This article is more than 5 years old. Information may no longer be current.

Provectus ocular melanoma treatment gets orphan drug designation

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has granted an orphan drug designation to PV-10, Provectus BioPharmaceuticals’ ocular melanoma treatment candidate, according to a press release.

Rose bengal disodium, also called PV-10, is a small molecule oncolytic immunotherapy delivered via intratumoral injection, which can yield immunogenic cell death in solid tumor cancers and stimulate tumor-specific reactivity in circulating T cells.

Preliminary data from a phase 1 basket study of PV-10 in four patients with metastatic cancer to the liver yielded tumor reduction in five of six injected tumors. The data were presented at the 15th International Congress of the Society for Melanoma Research in Manchester, England.

Further clinical studies are ongoing.

Reference: Patel SP, et al. Percutaneous oncolytic rose bengal disodium for metastatic uveal melanoma patients with hepatic metastases. Presented at: 15th International Congress of the Society for Melanoma Research; Oct. 24-27, 2018; Manchester, England.